New Understanding of Congenital Heart Disease Progression Opens Door to Improved Treatment Options

A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered new insights into the mechanisms underlying the progression of congenital heart disease (CHD) ― a spectrum of heart defects that develop before birth and remain the leading cause of childhood death.

Low Oxygen at Birth Delays Heart Development in Mouse Model of Congenital Heart Disease

Article title: Chronic perinatal hypoxia delays cardiac maturation in a mouse model for cyanotic congenital heart disease Authors: Jennifer Romanowicz, Devon Guerrelli, Zaenab Dhari, Colm Mulvany, Marissa Reilly, Luther Swift, Nimisha Vasandani, Manelle Ramadan, Linda Leatherbury, Nobuyuki Ishibashi, Nikki Gillum…

Lifetime Monitoring Following Infant Cardiac Surgery May Reduce Future Hypertension Risk

In a medical records study covering thousands of children, a U.S.-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function, it also may be associated with an increased risk of hypertension — high blood pressure — within a few months or years after surgery.

Research News Tip Sheet: Story Ideas From Johns Hopkins

During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.

Young Age Does Not Equal Low Risk for Patients Needing Aortic Valve Replacement

While transcatheter aortic valve replacement (TAVR) continues to expand its pool of eligible patients, open heart surgery—resulting in excellent patient survival and fewer strokes when compared to TAVR—is the best option for young and middle-aged adults with aortic valve disease—at least for now.

Teens with Heart Disease Improve Exercise Capacity in Large Clinical Trial

The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart defects. A study leader says the physiologic benefits represent a milestone in pediatric cardiology.